ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
84.71
-0.29 (-0.34%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close85.00
Open84.78
Bid0.00 x 800
Ask84.74 x 1100
Day's Range84.64 - 85.33
52 Week Range60.32 - 85.36
Volume4,522,756
Avg. Volume5,182,885
Market Cap149.444B
Beta (3Y Monthly)0.85
PE Ratio (TTM)57.47
EPS (TTM)1.47
Earnings DateJul 17, 2019
Forward Dividend & Yield1.28 (1.51%)
Ex-Dividend Date2019-07-12
1y Target Est83.06
Trade prices are not sourced from all markets
  • Financial Times2 hours ago

    Smith & Nephew directors discussed US listing to boost CEO pay

    Smith & Nephew board members have discussed moving the company’s share listing to the US, partly to escape the UK’s stricter attitude towards executive pay. According to two people familiar with the matter, the discussion over a listing change was prompted in part by efforts to narrow the gap between Mr Nawana’s pay at his former company Alere and his current role at the FTSE 100 medical devices maker, which he joined last May. As chief executive of Alere, a US medical diagnostics company, Mr Nawana earned a $8.6m pay package in 2016 and $11.1m in 2015.

  • PR Newswire17 hours ago

    Nutrition Is the Missing Ingredient in Home Health Today, New Study Shows

    ABBOTT PARK, Ill., June 24, 2019 /PRNewswire/ -- New research from Advocate Health Care and Abbott (ABT) found that prioritizing nutrition care* for home health patients at risk for malnutrition had a dramatic impact on helping keep them out of the hospital - resulting in millions of dollars in healthcare cost savings. Nearly 5 million Americans annually rely on home healthcare to recover from an illness, injury or hospitalization.1,† While healthcare providers are constantly striving to improve patients' health and minimize hospitalizations, nutrition is often not top of mind, yet it plays a critical role in helping adults bounce back and resume their normal routine.

  • PR Newswire6 days ago

    Abbott Hosts Conference Call for Second-Quarter Earnings

    ABBOTT PARK, Ill., June 19, 2019 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019 , before the market opens.  The announcement will ...

  • Is Abbott Laboratories a Buy?
    Motley Fool6 days ago

    Is Abbott Laboratories a Buy?

    This stock hasn't delivered much excitement, just great returns.

  • How Do Rate Cuts Impact Healthcare Stocks?
    Market Realist6 days ago

    How Do Rate Cuts Impact Healthcare Stocks?

    Barclays expects the Fed to cut the rate by 50 basis points in July—three months earlier than previously expected. Barclays expects an additional rate cut by 25 basis points in September.

  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks7 days ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed at $83.42 in the latest trading session, marking a +1.67% move from the prior day.

  • PR Newswire8 days ago

    CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings

    ATLANTA and ABBOTT PARK, Ill., June 17, 2019 /PRNewswire/ -- The global humanitarian organization CARE, the healthcare company Abbott (ABT) and its foundation the Abbott Fund today announced a three-year, $1 million program to screen, diagnose, prevent and manage noncommunicable diseases (NCDs) for people who remain displaced two years after armed conflict in Marawi City, Philippines. The partnership is among the first of its kind to address NCDs in areas affected by disasters, conflict and other humanitarian challenges.

  • PR Newswire8 days ago

    Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes

    - Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation - Assay is the first and only rapid point-of-care ...

  • Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers
    Zacks8 days ago

    Abbott (ABT) Hits New 52-Week High on Solid Growth Drivers

    Abbott (ABT) gains from expansion of product portfolio and several regulatory clearances.

  • PR Newswire11 days ago

    Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend

    ABBOTT PARK, Ill., June 14, 2019 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share. This marks the 382 nd consecutive quarterly ...

  • Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade
    Zacks12 days ago

    Abbott (ABT) Moves to Buy: Rationale Behind the Upgrade

    Abbott (ABT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).

  • PR Newswire12 days ago

    New Survey Shows Millennials Can Help Avoid Blood Shortages

    ABBOTT PARK, Ill., June 13, 2019 /PRNewswire/ -- A new survey from Abbott (ABT) finds that millennials may be the key to a growing public health problem: a shortage in donated blood. Historically, 45% of blood donations in the U.S. are from people 50 and older.1 A large portion of these regular donors are baby boomers who are starting to reach an age when they develop health problems that make them ineligible to give blood. "Millennials are known for wanting to positively impact global issues, and we are hoping to see that passion applied to donating blood," said Alexander Carterson, M.D., Ph.D., global medical director, Transfusion Medicine, Abbott.

  • Traders Look to Buy Global Health Care Stocks
    Investopedia13 days ago

    Traders Look to Buy Global Health Care Stocks

    The patterns forming on the long-term charts suggest that the global health care sector could be poised for a prolonged move higher.

  • Here’s What Hedge Funds Think About Abbott Laboratories (ABT)
    Insider Monkey15 days ago

    Here’s What Hedge Funds Think About Abbott Laboratories (ABT)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life
    Zacks15 days ago

    The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

    The Zacks Analyst Blog Highlights: Mastercard, Disney, Abbott, Workday and Sun Life

  • Markit15 days ago

    See what the IHS Markit Score report has to say about Abbott Laboratories.

    Abbott Laboratories NYSE:ABTView full report here! Summary * Perception of the company's creditworthiness is negative * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for ABT with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting ABT. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding ABT totaled $4.38 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NegativeThe current level displays a negative indicator. ABT credit default swap spreads are at their highest levels for the past 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Where Will Abbott Laboratories Be in 10 Years?
    Motley Fool16 days ago

    Where Will Abbott Laboratories Be in 10 Years?

    Expect the healthcare giant to hew to the principles that lifted it to where it stands now.

  • Reuters17 days ago

    CORRECTED-Abbott device helps in cutting blood sugar in type 2 diabetics - study (June 8)

    Insulin-dependent patients with type 2 diabetes saw a significant drop in their blood sugar levels after wearing Abbott Laboratories Inc's continuous glucose monitoring system for three months compared with when they were not using the device, researchers said on Saturday. The study, which was presented at the American Diabetes Association meeting in San Francisco, assessed the medical records of 363 type 2 diabetics in France, Germany and Austria between three and six months. Dr. Helene Hanaire of the University Hospital Center of Toulouse, France, one of the study authors, said having ready access to their blood glucose readings helped diabetics become more engaged with controlling their glucose levels.

  • PR Newswire17 days ago

    New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes

    SAN FRANCISCO, June 8, 2019 /PRNewswire/ -- Today Abbott (ABT) announced new data showing use of its FreeStyle Libre system, the company's revolutionary continuous glucose monitoring (CGM) technology, significantly reduced hemoglobin A1c (HbA1c) levels for people living with Type 2 diabetes on intensive insulin therapy.2 The results were analyzed from retrospective, real-world data in three countries across Europe and presented as a late-breaker (Abstract 99-LB) at the American Diabetes Association (ADA) 79th Scientific Sessions in San Francisco. The goal of the combined analysis of three individual studies was to determine the impact of using the FreeStyle Libre system on glycemic control in people on intensive insulin therapy living with Type 2 diabetes, the most common form of diabetes where the body is unable to make enough insulin to keep blood glucose levels normal.

  • Top Research Reports for Mastercard, Disney & Abbott
    Zacks18 days ago

    Top Research Reports for Mastercard, Disney & Abbott

    Top Research Reports for Mastercard, Disney & Abbott

  • Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?
    Zacks19 days ago

    Is Abbott Laboratories (ABT) Outperforming Other Medical Stocks This Year?

    Is (ABT) Outperforming Other Medical Stocks This Year?

  • Abbott (ABT) Gains But Lags Market: What You Should Know
    Zacks21 days ago

    Abbott (ABT) Gains But Lags Market: What You Should Know

    Abbott (ABT) closed at $77.54 in the latest trading session, marking a +1.85% move from the prior day.

  • Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges
    Zacks21 days ago

    Abbott (ABT) Grows on EPD Amid Rhythm Management Challenges

    We are optimistic about the steady growth trend in Abbott's (ABT) EPD and Medical Devices segments on an organic basis.

  • Did Abbott Laboratories (NYSE:ABT) Use Debt To Deliver Its ROE Of 8.3%?
    Simply Wall St.22 days ago

    Did Abbott Laboratories (NYSE:ABT) Use Debt To Deliver Its ROE Of 8.3%?

    While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...